# FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Source: https://onco.cc/trials/nct02448381/  
OnCo record `nct02448381` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Synthetic hypericin in Cutaneous T-cell lymphoma, run by Soligenix, completed.

## Summary

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) is a phase 3 interventional study registered as NCT02448381 by Soligenix, with 169 participants recorded, started 2015-12 and reaching its primary completion in 2020-06. Interventions recorded: SGX301 (synthetic hypericin), Placebo. Conditions recorded: Cutaneous T-Cell Lymphoma.

Linked to the drug Synthetic hypericin because the registry names it among its interventions and Cutaneous T-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02448381
- Phase: 3
- Setting: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma
- Sponsor: Soligenix
- Enrolled: 169

## Sources

- ClinicalTrials.gov NCT02448381: https://clinicaltrials.gov/study/NCT02448381

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/)
- drugs: [Synthetic hypericin](https://onco.cc/drugs/hypericin-sgx301/)
- companies: [Soligenix](https://onco.cc/companies/soligenix/)

---
JSON: https://onco.cc/api/v1/entities/nct02448381.json